Oncology Precision Medicine Market

Oncology Precision Medicine Market

Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted (Bladder Cancer, Blood / Hematologic Cancer, Breast Cancer, Cervical Cancer, Gastrointestinal Cancer, Head and Neck Squamous Cell Cancer, Lung Cancer, Skin Cancer and Others), Route of Administration (Oral, Intravenous and Others), Type of Molecule (Small Molecules and Biologics), Drug Class (Kinase Inhibitors, Enzyme Inhibitors, Immune Checkpoint Inhibitors and Others), Key Geographical Regions (North America (US, Canada), Europe (France, Germany, Italy, Spain and UK), Asia (China, Japan, Korea and India), Middle East and North Africa (UAE, Israel, Qatar, Rest of Middle East and North Africa) and Latin America (Brazil, Argentina, Chile and Rest of Latin America), Leading Drug Developers and Sales ForecastThe oncology precision medicine market is expected to reach USD 130 billion by 2023 anticipated to grow at a CAGR of 8.93% during the forecast period 2023-2035.

Cancer is widely recognized as a highly lethal disease, characterized by its widespread occurrence and high mortality rates on a global scale. According to data from the World Health Organization, the year 2020 saw approximately 20 million new cases of cancer and 10 million cancer-related deaths reported. Projections indicate a staggering 60% increase in these figures by the year 2040. The increase in cancer prevalence and pathogenesis can be attributed to various factors such as alcohol consumption, obesity, viral infections, and exposure to radiation and chemicals. Traditional treatment methods for cancer, including surgery, radiation therapy, and chemotherapy, are commonly employed. Complementary or alternative therapeutic approaches such as hormone therapy, immunotherapy, and nano therapy are also utilized. However, these treatments have limitations in addressing the intrinsic genetic abnormalities underlying cancer, which may stem from specific mutations in oncogenes, tumor suppressor genes, and DNA repair genes.

To address the limitations of existing treatments, the concept of precision medicine, also known as personalized medicine, has emerged. Precision medicine utilizes genomic information to develop targeted therapies tailored to individual patients. By analyzing tumor characteristics, genetic data, patient lifestyle, and environmental factors, precision medicine offers promising potential in treating cancer by moving away from a one-size-fits-all approach. Individuals with a family history of certain cancers are at a higher risk of inheriting the condition, and precision oncology enables them to undergo genetic testing to assess their risk. Early cancer screening facilitates early detection, leading to improved treatment outcomes. Notably, several precision cancer centers in the US, such as MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Mayo Clinic Cancer Center, provide advanced technologies and treatments tailored for patients with rare or challenging cancers. Clinical trials of oncology precision medicines have demonstrated high efficacy, leading to increased participation of volunteers and consequently expanding the patient pool in such trials. This aids researchers in making better-informed decisions regarding evaluated drugs or technologies. With ongoing research and innovation in precision medicine, there is an anticipated significant increase in the adoption of targeted drugs, thereby driving growth in the oncology precision medicine market in the foreseeable future.Report Coverage

The report comprehensively examines the oncology in precision market based on type of cancer targeted route of administration, type of molecule, drug class, key geographical regions.

It thoroughly analyzes market influences such as drivers, restraints, opportunities, and challenges, while evaluating competitive landscapes for top players. Forecasts are provided for segment revenues across major regions.

The report presents an overview of precision medicine, specifically in the oncology field, comparing it to traditional cancer medications. It outlines the process of developing oncology precision medicines, discussing their advantages and anticipated significance in shaping the future of personalized healthcare. Challenges associated with oncology precision medicine are also addressed.

An overview of precision medicine in oncology is provided, covering its evolution, types, and application areas. The chapter also discusses the benefits of these procedures compared to traditional beauty treatments, along with their associated side effects. Key drivers of growth, new technologies, key issues, and future prospects in this field are also covered.

A comprehensive analysis of current oncology precision medicine developers is conducted, considering parameters such as establishment year, company size, headquarters, stage of development, approval body, approval region, drug designation, type of molecule, drug class, route of administration, dosage regimen, patient population, and type of cancer targeted. Additionally, the chapter presents a detailed analysis of the current landscape of discovery and preclinical stage oncology precision medicines, based on parameters such as stage of development, type of molecule, drug class, and type of cancer targeted.

Detailed profiles of companies offering precision medicine are presented, focusing on company overviews, financial information (where available), portfolio, recent advancements, and future prospects.

An analysis of partnerships established in this sector since 2018 is conducted, covering various agreements such as clinical trial agreements, commercialization agreements, drug development agreements, drug distribution agreements, drug licensing agreements, manufacturing agreements, mergers/acquisitions, process development and manufacturing agreements, research agreements, research and development agreements, service agreements, technology utilization agreements, and others.

Detail examination of completed or ongoing clinical trials in the field of oncology precision medicine is conducted, focusing on parameters such as trial registration year, patient enrollment numbers, trial phase, status, target patient demographics, gender distribution, types of cancer targeted, sponsorship or collaboration types, study design characteristics, intervention models, and trial purposes. The analysis also identifies the most active sponsors or collaborators, comprising both industry and non-industry players based on their sponsorship of clinical trials. Additionally, emerging focus areas and geographical trends are explored within this clinical trial analysis.

A case study is presented on developers of precision oncology assay kits, offering a detailed analysis across several parameters including development stage (commercialized and under development), regulatory certification and compliance, regional availability, test type, sample type, biomarker detection principle, turnaround time, cancer type targeted, and end-user demographics. Furthermore, the chapter includes insights on various assay kit developers, along with an analysis based on parameters such as establishment year, company size, and headquarters location.

Key Market Companies

AbbVie

Anticancer Bioscience

Astellas Pharma

Astrazeneca

Bayer

Blueprint Medicines

Bristol Myers Squibb

Eli Lilly

Erasca

Genentech

GlaxoSmithKline

Hutchmed

IDEAYA Biosciences

Jiangsu Hengrui Pharmaceuticals

Johnson & Johnson Innovative Medicine

Merck

Novartis

Pfizer

Repare Therapeutics

Roche

Seagen

SpringWorks Therapeutics

Takeda Pharmaceutical

VERAXA Biotech GmbH

VRise Therapeutics